Recent Patents on Novel MCH1 Receptor Antagonists as Potential Anti-Obesity Drugs.

Recent Patents on Novel MCH1 Receptor Antagonists as Potential Anti-Obesity Drugs. Recent Pat CNS Drug Discov. 2014 Jun 13; Authors: Szalai KK, Beke G, Eles J, Kitka T, Nagy J, Farkas S, Boros A Abstract Today, the "obesity pandemic" is one of the biggest health issues around the world. As hypothalamic neuropeptide melanin-concentrating hormone (MCH) is one of the most potent central stimulators of feeding, regulating energy balance, inhibition of its receptor, melanin concentrating hormone receptor-1 (MCHR1), has attracted considerable attention during the last decade. There are is now a great selection of known MCHR1 antagonists that provide clues to for the development of new structures with high potency and good pharmacokinetic profiles. Several well described in vitro and in vivo pharmacological tools and clinical drug candidates are also available. The function of MCHR1 in energy homeostasis and its role in obesity and metabolic syndrome, as well as in mood and inflammatory bowel disorders, are discussed. Relevant clinical trials and the patent background of its antagonists over the last 4 years are also revisited. PMID: 24924101 [PubMed - as supplied by publisher]
Source: Recent Patents on CNS Drug Discovery - Category: Drugs & Pharmacology Tags: Recent Pat CNS Drug Discov Source Type: research